TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024 09:10 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024 08:30 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Jowin, the Apple in Korea’s cancer treatment, expands their business globally
February 21, 2023 06:06 ET
|
JOWIN
Korea's innovative venture company Jowin declares its expansion into the global cancer care market through the establishment of a global telemedicine platform.A telemedicine platform for overseas...
MetasTx LLC Raises Funds, Engages Manufacturing Partner, And Advances Phase One Development
June 07, 2022 07:22 ET
|
MetasTx LLC
BASKING RIDGE, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers. Harvey Homan, CEO and Co-Founder has...
Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
June 03, 2019 16:05 ET
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...
Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019
June 03, 2019 09:05 ET
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...